These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder. Sharma RP; Janicak PG; Bissette G; Nemeroff CB Am J Psychiatry; 1997 Jul; 154(7):1019-21. PubMed ID: 9210757 [TBL] [Abstract][Full Text] [Related]
5. Subnormal CSF levels of neurotensin in a subgroup of schizophrenic patients: normalization after neuroleptic treatment. Widerlöv E; Lindström LH; Besev G; Manberg PJ; Nemeroff CB; Breese GR; Kizer JS; Prange AJ Am J Psychiatry; 1982 Sep; 139(9):1122-6. PubMed ID: 6126127 [No Abstract] [Full Text] [Related]
6. Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients. Garver DL; Bissette G; Yao JK; Nemeroff CB Am J Psychiatry; 1991 Apr; 148(4):484-8. PubMed ID: 2006695 [TBL] [Abstract][Full Text] [Related]
7. Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment. Kahn RS; Davidson M; Knott P; Stern RG; Apter S; Davis KL Arch Gen Psychiatry; 1993 Aug; 50(8):599-605. PubMed ID: 7688208 [TBL] [Abstract][Full Text] [Related]
8. CSF levels of HVA and 5-HIAA in drug-free schizophrenic patients and healthy controls: a prospective study focused on their predictive value for outcome in schizophrenia. Wieselgren IM; Lindström LH Psychiatry Res; 1998 Nov; 81(2):101-10. PubMed ID: 9858027 [TBL] [Abstract][Full Text] [Related]
9. The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients. Scheepers FE; Gispen-de Wied CC; Westenberg HG; Kahn RS Neuropsychopharmacology; 2001 Oct; 25(4):468-75. PubMed ID: 11557160 [TBL] [Abstract][Full Text] [Related]
10. Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics. Hsiao JK; Colison J; Bartko JJ; Doran AR; Konicki PE; Potter WZ; Pickar D Arch Gen Psychiatry; 1993 Aug; 50(8):606-14. PubMed ID: 7688209 [TBL] [Abstract][Full Text] [Related]
11. Relationship between abnormal brainstem auditory-evoked potentials and subnormal CSF levels of HVA and 5-HIAA in first-episode schizophrenic patients. Lindström LH; Wieselgren IM; Klockhoff I; Svedberg A Biol Psychiatry; 1990 Sep; 28(5):435-42. PubMed ID: 1698468 [TBL] [Abstract][Full Text] [Related]
12. Concentrations of monoamine metabolites and chlorpromazine in cerebrospinal fluid for prediction of therapeutic response in psychotic patients treated with neuroleptic drugs. Sedvall G Prog Biochem Pharmacol; 1980; 16():133-40. PubMed ID: 6160594 [TBL] [Abstract][Full Text] [Related]
13. Effect of chlorpromazine treatment on monoamine metabolite levels in cerebrospinal fluid of psychotic patients. Wode-Helgodt B; Fyrö B; Gullberg B; Sedvall G Acta Psychiatr Scand; 1977 Aug; 56(2):129-42. PubMed ID: 899844 [TBL] [Abstract][Full Text] [Related]
14. Aberrant monoamine metabolite levels in CSF and family history of schizophrenia. Their relationships in schizophrenic patients. Sedvall GC; Wode-Helgodt B Arch Gen Psychiatry; 1980 Oct; 37(10):1113-6. PubMed ID: 6158928 [TBL] [Abstract][Full Text] [Related]
15. CSF levels of receptor-active endorphins in schizophrenic patients: correlations with symptomatology and monoamine metabolites. Lindström LH; Besev G; Gunne LM; Terenius L Psychiatry Res; 1986 Oct; 19(2):93-100. PubMed ID: 2431427 [TBL] [Abstract][Full Text] [Related]
16. The dopamine-serotonin relationship in clozapine response. Szymanski S; Lieberman J; Pollack S; Munne R; Safferman A; Kane J; Kronig M; Cooper T Psychopharmacology (Berl); 1993; 112(1 Suppl):S85-9. PubMed ID: 7530378 [TBL] [Abstract][Full Text] [Related]
17. Cholecystokinin and neurotensin gradients in human CSF. Tamminga CA; LeWitt PA; Chase TN Arch Neurol; 1985 Apr; 42(4):354-5. PubMed ID: 3985812 [TBL] [Abstract][Full Text] [Related]
18. No major influence of regular tobacco smoking on cerebrospinal fluid monoamine metabolite concentrations in patients with psychotic disorder and healthy individuals. Hjärpe J; Söderman E; Andreou D; Sedvall GC; Agartz I; Jönsson EG Psychiatry Res; 2018 May; 263():30-34. PubMed ID: 29482043 [TBL] [Abstract][Full Text] [Related]
19. Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. Nikisch G; Baumann P; Wiedemann G; Kiessling B; Weisser H; Hertel A; Yoshitake T; Kehr J; Mathé AA J Clin Psychopharmacol; 2010 Oct; 30(5):496-503. PubMed ID: 20814316 [TBL] [Abstract][Full Text] [Related]
20. Low HVA and normal 5HIAA CSF levels in drug-free schizophrenic patients compared to healthy volunteers: correlations to symptomatology and family history. Lindström LH Psychiatry Res; 1985 Apr; 14(4):265-73. PubMed ID: 2410940 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]